The effects of all three compounds for chronic myeloid leukemia (CML) were conducted in such a way that specifically evaluated changes of expression for DNMT1 and CDKN1A as well as the expression of tumor suppressor genes PTEN and RARB [113]. The gene discussed is DNMT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.